Assessment of the NAFLD activity score (NAS) components revealed beneficial effects of FGF21 administration on hepatic steatosis, which was confirmed by a lower hepatic triglyceride content, while CCR2/5 inhibitor treatment was associated with reduced lobular inflammation (Figure 2B,E,F). The gene discussed is CCR2; the disease is fatty liver disease.